CAJ | 학술논문

急性淋巴细胞白血病(ALL)是一组异质性疾病,其预后与患者年龄、免疫亚型、基因和分子生物学特征密切相关.第54届美国血液学会(ASH)年会大量报道了有关ALL发病机制、预后及治疗等领域的最新进展.对ALL的基因表达谱、靶向治疗及造血干细胞移植等方面的亮点进行介绍.
급성림파세포백혈병(ALL)시일조이질성질병,기예후여환자년령、면역아형、기인화분자생물학특정밀절상관.제54계미국혈액학회(ASH)년회대량보도료유관ALL발병궤제、예후급치료등영역적최신진전.대ALL적기인표체보、파향치료급조혈간세포이식등방면적량점진행개소.
Acute lymphoblastic leukemia (ALL) is a heterogeneous disease affected by patient' s age,immunologic subtype,genetic and molecular features.In the 54th ASH annual meeting,lots of new discoveries about the biology,prognosis and treatment of ALL were reported.Here highlights of genomic profiling,new targeted therapy and hematopoietic stem cell transplantation for ALL presented in this meeting are introduced.